Strides Pharma Science Ltd
Fortune 500 2024
+ 14 More
+ 14 More
Share
Share
OVERVIEW
FINANCIALS
NEWS
About
Strides Pharma Science Limited is a Bangalore-based pharmaceutical company that specialises in niche finished dosage formulations. The company focuses on developing and manufacturing soft gelatin capsules , providing it to both regulated and emerging markets worldwide. Strides operates 8 manufacturing facilities across 4 continents, 5 of which hold the distinction of being approved by the U.S FDA, thus ensuring compliance with global quality standards. The company has a worldwide presence, mainly catering to the regulated markets in the United States, Europe and Australia. Strides is publicly traded on the Bombay Stock Exchange (BSE: 532531) and the National Stock Exchange (NSE: STAR).
Incorporation Year: 1990
Headquarters: Bengaluru, Karnataka
Top Management: Arun Kumar
Industry: Pharma
Website: strides.com
Featured In Fortune India Ranking
Fortune 500 India
#497(2024)
#467(2023)
#457(2022)
#320(2021)
#367(2020)
#341(2019)
#335(2018)
#297(2017)
#317(2016)
#276(2014)
#303(2013)
#325(2012)
#381(2011)
#380(2010)
#497(2024)#467(2023)#457(2022)#320(2021)#367(2020)#341(2019)#335(2018)#297(2017)#317(2016)#276(2014)#303(2013)#325(2012)#381(2011)#380(2010)
Ranking Trend Fortune 500 India
Next 500 India
#34(2016)
#34(2016)
Financial Data 2024
Revenue
4,130
(INR Cr)
Net Operating Income
4,051
(INR Cr)
Assets
4,694
(INR Cr)
Profit
-71
(INR Cr)
Net Worth
2,126
(INR Cr)
Fortune India Coverage
Financial Data
RevenueNet Operating IncomeProfitAssetsNet Worth
| PARAMETERS | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (INR Cr) | 4130 4.9% | 3938 24.5% | 3164 -18.3% | 3873 31.1% | 2954 11.5% | 2650 -23.0% | 3443 6.0% | 3249 5.8% | 3072 45.3% | 2114 -54.3% | 4629 142.0% | 1913 -28.8% | 2684 47.0% | 1827 29.0% | 1416 -2.9% | 1458 - |
| Net Operating Income (INR Cr) | 4051 9.83% | 3688 20.13% | 3070 -7.41% | 3316 20.49% | 2752 26.33% | 2178 -23.43% | 2845 3.25% | 2755 -3.73% | 2862 139.34% | 1196 -10.82% | 1341 39.43% | 962 -62.28% | 2550 50.43% | 1695 30.04% | 1304 27.78% | 1020 37.13% |
| Profit (INR Cr) | -71 - | -203 - | -460 - | 268 637.7% | 36 -88.8% | 325 -51.2% | 665 66.2% | 400 268.4% | 109 -87.2% | 845 -52.2% | 1767 108.8% | 846 277.0% | 224 83.3% | 122 11.6% | 110 1.6% | 108 - |
| Assets (INR Cr) | 4694 -11.3% | 5290 -4.4% | 5531 0.8% | 5486 10.5% | 4963 -24.0% | 6527 17.5% | 5557 -20.7% | 7004 8.9% | 6433 209.4% | 2079 25.6% | 1656 -56.8% | 3835 -7.6% | 4152 16.5% | 3565 40.0% | 2546 34.3% | 1896 - |
| Net Worth (INR Cr) | 2126 -3.9% | 2212 -6.2% | 2359 -15.0% | 2777 9.9% | 2527 -4.6% | 2649 7.5% | 2464 -10.4% | 2749 3.4% | 2658 132.1% | 1145 13.7% | 1007 -50.3% | 2026 47.7% | 1371 6.9% | 1283 64.1% | 782 114.5% | 364 75.3% |
| Employee Cost (INR Cr) | 751 2.6% | 732 13.2% | 647 17.6% | 550 24.3% | 443 34.3% | 329 -24.1% | 434 3.6% | 419 17.2% | 358 107.9% | 172 9.5% | 157 30.7% | 120 -60.3% | 303 34.6% | 225 24.4% | 181 0.5% | 180 - |
| Interest Cost (INR Cr) | 314 | 261 | 177 | 150 | 156 | 79 | 196 | 183 | 168 | 47 | 109 | 79 | 195 | 147 | 76 | 85 |
| Cash & Bank Balance (INR Cr) | 191 | 316 | 187 | 180 | 237 | 517 | 303 | 329 | 312 | 147 | 231 | 166 | 260 | 339 | 91 | 57 |
| Total Debt (INR Cr) | 2517 | 3030 | 3025 | 2348 | 2235 | 3221 | 2520 | 3700 | 3542 | 892 | 547 | 1594 | 2643 | 2010 | 1457 | 1302 |
Key Financial Ratios
Profit As % Of RevenuesRONW %Interest Cost to EBITDA %ROCE %Debt to Equity Ratio
| PARAMETERS | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Profit As % Of Revenues | - | - | - | 6.9% | 1.2% | 12.3% | 19.3% | 12.3% | 3.5% | 40.0% | 38.2% | 44.2% | 8.4% | 6.7% | 7.7% | 7.4% |
| Profit As % Of Assets | - | - | - | 4.9% | 0.7% | 5.0% | 12.0% | 5.7% | 1.7% | 40.6% | 106.7% | 22.1% | 5.4% | 3.4% | 4.3% | 5.7% |
| Profit As % Of Networth | - | - | - | 9.7% | 1.4% | 12.3% | 27.0% | 14.5% | 4.1% | 73.8% | 175.5% | 41.8% | 16.4% | 9.6% | 14.0% | 29.6% |
| Interest Cost to EBITDA % | 83.2% | - | - | 33.9% | 72.8% | 59.9% | 56.0% | 38.5% | 49.8% | 23.7% | - | 79.0% | 39.9% | 47.2% | 41.8% | - |
| Debt to Equity Ratio | 1.18 | 1.37 | 1.28 | 0.85 | 0.88 | 1.22 | 1.02 | 1.35 | 1.33 | 0.78 | 0.54 | 0.79 | 1.93 | 1.57 | 1.86 | 3.57 |
| RONW | - | - | - | 8.1% | 3.1% | 11.8% | 26.3% | 16.1% | 5.8% | 53.7% | 76.3% | 48.2% | 13.3% | 10.9% | 8.4% | 12.1% |
| ROCE | 0.0% | 0.0% | -4.4% | 7.6% | 4.9% | 6.0% | 14.4% | 10.3% | 8.2% | 44.9% | 79.8% | 25.8% | 10.8% | 10.9% | 7.3% | 7.9% |